Zealand Pharma CEO believes in firm's obesity efforts

Adam Steensberg, the CEO of Zealand Pharma, says that the firm’s three candidates within the indication make the firm an interesting player on the obesity market.

Photo: PR-foto Zealand Pharma

Private wealth manager Bernstein has previously predicted that the obesity market in the US could be worth up to DKK 500bn (USD 72bn) within ten years – and Zealand Pharma wants in.

”If you look around, a lot of the large companies are realizing that they should get into obesity treatments, but they don’t have a pipeline. In that respect, Zealand Pharma is a relatively interesting player to team up with for access,” CEO Adam Steensberg tells Danish financial daily Børsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs